Rare
lephants
Screener
Toggle theme
Gyre Therapeutics, Inc.
GYRE
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2023
FY2022
FY2010
Total Cash from Operations:
$45.0M
Line Item
Value
% of Total
Capital Expenditures
$1.2M
2.6%
Working Capital
$18.5M
41.2%
Net Cash Flow
$25.3M
56.2%
Download CSV
